Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T07:58:55.020Z Has data issue: false hasContentIssue false
  • English
  • Français

Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months

Published online by Cambridge University Press:  16 April 2020

P Lemoine ,
H Allain ,
C Janus  and
P Sutet
P Lemoine
Affiliation:
UCPB, CHS Le Vinatier, 95 rue Pinel, 69677Lyon-Bron Cedex, France
H Allain
Affiliation:
Laboratoire de Pharmacologie, CHRU Pontchaillou, 35000Rennes, France
C Janus
Affiliation:
Théraplix, 46-52 rue Albert, 75013Paris, France
P Sutet
Affiliation:
UCPB, CHS Le Vinatier, 95 rue Pinel, 69677Lyon-Bron Cedex, France
Get access

Summary

Two distinct double-blind randomized multicentre studies were undertaken at the same time using the same design. Patients treated for insomnia with zopiclone 7.5 mg or zolpidem 10 mg for at least three months were allocated to two groups: gradual withdrawal or control. In each study the two groups were compared but there was no comparison between zopiclone and zolpidem. The main criteria was the number of patients in each group with “withdrawal syndrome” defined as: the occurrence of an adverse event, or premature discontinuation of treatment or a total score increase of at least 3 points on the Tyrer questionnaire. In both studies the incidence of “withdrawal syndrome” as defined above was significantly higher in the “withdrawal” groups than in the “control” groups 38% vs 20% for zopiclone p = 0.008 and 38% vs 24% for zolpidem P = 0.049. In most cases, the notified symptoms were sleep complaints.

Keywords

withdrawalzopiclonezolpideminsomnia
Type
Research Article
Information
European Psychiatry , Volume 10 , Issue S3: Satellite Symposium to the AEP Congress , 1995 , pp. 161s - 165s
Copyright
Copyright © Elsevier, Paris 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association Task force on benzodiazepine, dependence, toxicity and abuse Washington: APA Press, 1990Google Scholar
Ashton, HBenzodiazepine withdrawal: an unfinished story. Bro Med J 1984; 288: 1135–40CrossRefGoogle Scholar
Benoit, OBénéfices et inconvénients des hypnotiques. Neurophysiol Clin 1991;21(4):245–CrossRefGoogle Scholar
Bianchi, MMusch, BZopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 1990; 5(suppl 2):139–45Google ScholarPubMed
Bisserbe, JCBoulenger, J.P.Non benzodiazepine anxiolytics and hypnotics acting at the benzodiazepine-GABA macromolecularcomplex: alpidem, zolpidem, zopiclone. Clin Neuropharmacol 1990; 13(suppl 2):77–8Google Scholar
Bornstein, SDelahaye, CMaillard, FComparaison des effets de zopiclone 7.5 mg et de triazolam 0.5 0 mg administrés à des patients insomniaques traités en ambulatoire. Neuro Psy 1988; 9: 429–35Google Scholar
Dietch, JThe nature and extent of benzodiazepine abuse: an overview of recent literature. Hosp Community Psychiatry 1983; 34(12): 1139–1145Google ScholarPubMed
Elie, RLavoie, GBourgouin, JLe Morvan, PZopiclone versus flurazepam in insomnia: prolonged administration and withdrawalInt. Clin Psychopharmacol 1990; 5: 279–86CrossRefGoogle Scholar
Lader, MFracka, GSubjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 2021987 67–71CrossRefGoogle ScholarPubMed
Lemoine, PDeluermoz, SMouret, JBien prescrire les psychotropes. Les hypnotiques: insomnie, insomniaques et induction du sommeil. Concours Med 11431992 187–94Google Scholar
Lemoine, PLe sevrage des hypnotiques, application de la zopiclone. In: Grivois, H, et al. Zopiclone 1987–1992: 5 années de pratique clinique Paris: Elsevier, 1992 137–52Google Scholar
Zurich Lépine, JPBoyer, PRein, WDreyfus, JFA French national survey of tranquillizers users. VIth European symposium on psychiatric epidemiology and social psychiatry 1992Google Scholar
Mellinger, GDBaiter, MBUhlenhuth, EHInsomnia and its treatment. Arch Gen Psychiatry 4231985 225–32CrossRefGoogle ScholarPubMed
Munich Oswald, IAdams, KIndividual differences and hypnotics. Psychopharmacology, XVI CINP Congress 1988;TU 08.03:21Google Scholar
Pelissolo, ABisserbe, JCDépendance aux benzodiazépines. Encephale 1994; 20: 147–57Google Scholar
Uhlenhuth, EHDewit, HBalter, MBJohanson, CEMellinger, GDRisks and benefits of long term benzodiazepines use. J Clin Psychopharmacol 1988; 8: 161–7CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.